Treg: Regulatory T Cells and T Helper Cells

Our proprietary technology platform represents a novel potential treatment option for a wide range of chronic inflammatory diseases.

Product candidates

We are focusing on chronic inflammatory diseases where current treatments show limited efficacy, limited tolerability and for which 30% of the patients treated develop resistance.

Inflammatory Bowel Disease, primarily treatment resistant Crohn’s Disease
Ovasave® is our lead product candidate. The first in man, open label, phase I/II clinical trial for severe refractory Crohn's Disease patients has been completed (link1) (link2) and showed good tolerability and a strong efficacy signal in the best dose group. A phase IIb placebo controlled study is planned in the same patient population.

Neurological Diseases, targeting Multiple Sclerosis
TX-MSD, our second product candidate is in pre-clinical stage of development.

Inflammatory Joint Diseases, targeting resistant Rheumatoid Arthritis
TX-RAD, our third product candidate is in pre-clinical stage of development.